Record Details

The Crossroad between Intellectual Property and Clinical Trials: Balancing Incentives for Innovation with Access to Healthcare

NOPR - NISCAIR Online Periodicals Repository

View Archive Info
 
 
Field Value
 
Title The Crossroad between Intellectual Property and Clinical Trials: Balancing Incentives for Innovation with Access to Healthcare
 
Creator Nidhi, Aditi
 
Subject Intellectual Property
Clinical Trials
Clinical Trials
Access to Healthcare
Pharmaceutical Industry
Patents
Exclusivity
Open-Source Drug Development
Prize-Based Systems
 
Description 284-292
Intellectual property (IP) is essential for encouraging innovation in the pharmaceutical business, particularly in clinical
trials. However, IP can also limit access to healthcare by making drugs and treatments unaffordable for certain populations.
The pharmaceutical industry relies heavily on intellectual property protections to incentivize innovation and support the
development of new drugs. Moreover, clinical trials play an indispensable part in the medication development process,
providing the evidence needed to support regulatory approval and marketing. The intersection of intellectual property and
clinical trials raises important legal and ethical issues that need to be carefully considered. This article analyses the
significance of intellectual property in the process of drug innovation, its impact on clinical trials, and the ways in which
intellectual property might affect the accessibility and price of new treatments. This paper also explores the balance between
incentivizing innovation through IP and ensuring access to healthcare, notably within the setting of clinical trials.
It examines the history of intellectual property laws in the pharmaceutical industry, how patents and exclusivity
encourage innovation, and how these incentives affect healthcare access. The paper also discusses alternative models for
incentivizing innovation, such as open-source drug development and prize-based systems. The article concludes that while
intellectual property is vital to encourage innovation in the pharmaceutical business, it must be balanced with efforts to
assure universal access to healthcare. We argue that policymakers and industry stakeholders must work together to develop
policies and practices that promote innovation while ensuring that new drugs are accessible and affordable to all.
 
Date 2023-06-28T10:23:05Z
2023-06-28T10:23:09Z
2023-06-28T10:23:05Z
2023-06-28T10:23:09Z
2023-06
 
Type Article
 
Identifier 0975-1076 (Online); 0971-7544 (Print)
http://nopr.niscpr.res.in/handle/123456789/62142
https://doi.org/10.56042/jipr.v28i4.77
 
Language en
 
Publisher NIScPR-CSIR,India
 
Source JIPR Vol.28(4) [July 2023]